Despite maintaining steady capital expenditure and fiscal deficit targets, analysts predict that significant tax policy changes, particular...

In her Budget speech, Sitharaman said the government, in partnership with states, will promote digital public infra for agriculture. Follow...

But otherwise, automobiles, banks, pharmaceuticals, capital goods they have all delivered on numbers. Metals and oil and gas was again supp...

Orchid Pharma, backed by Dhanuka Group, focuses on cephalosporin antibiotics. Expansion plans include a new facility, Enmetazobactam launch...

The Chennai-based firm said Exblifeb incorporates Enmetazobactam, "the first completely invented-in-India Beta Lactamase inhibitor" and it ...

“Three years back, when we started, we had a significant debt. But, today we are a debt-free company and we also have significant investmen...

ET Global Indian Leaders is a celebration of professional and entrepreneurial excellence across multiple sectors and industries.

Nirali Shah of Samco Securities said the index has established short-term support at 15,500 level, and a breach of this level will raise th...

Nifty managed to top the 15,900 level in intraday trade, but failed to hold the gains and ended above the 15,800 level.

Nifty moved in a wide range of 311 points and formed a ‘Hammer’ candle on the daily chart and an indecisive 'Doji' on the weekly scale. Ana...

Sensex slipped below the 52,000 mark, while Nifty ended below the crucial 15,550 level.

Manish Hathiramani, Technical Analyst at Deen Dayal Investments, said, a breach of the 15,300 level can open up doors for 15,550-15,600 lev...

Shrikant Chouhan, Executive Vice President (Equity Technical Research), Kotak Securities said, “On the downside, 13,000 and 12,930 would be...

Mazhar Mohammad of Chartviewindia.in said, in next trading session, if the index settles below 12,800 levels on closing basis, then it may ...

Ajit Mishra of Religare Broking said, the rebound in Nifty indicates that the prevailing consolidation phase will continue.

Ambit Capital has maintained sell rating on Bharti Airtel with a target price of Rs 284.